Precision BioSciences (DTIL) 10-Q 13 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 06, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020
Entity Registrant Name	PRECISION BIOSCIENCES INC
Entity Central Index Key	0001357874
Trading Symbol	DTIL
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Common Stock, Shares Outstanding		52,344,813
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Ex Transition Period	false
Entity File Number	001-38841
Entity Tax Identification Number	20-4206017
Entity Address, Address Line One	302 East Pettigrew St.
Entity Address, Address Line Two	Suite A-100
Entity Address, City or Town	Durham
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	27701
City Area Code	919
Local Phone Number	314-5512
Title of 12(b) Security	Common Stock, par value $0.000005 per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 126,886	$ 180,886
Accounts receivable	83	965
Prepaid expenses	10,184	9,497
Other current assets	240	2,324
Total current assets	137,393	193,672
Property, equipment, and software—net	37,541	39,571
Intangible assets—net	1,402	1,432
Right-of-use assets	6,495
Other assets	1,361	558
Total assets	184,192	235,233
Current liabilities:
Accounts payable	1,587	2,037
Accrued compensation	3,343	4,425
Accrued clinical and research and development expenses	3,118	2,400
Accrued other expenses and other current liabilities	1,403	1,584
Deferred revenue	23,060	16,486
Lease liabilities	1,800
Total current liabilities	34,311	26,932
Deferred revenue—noncurrent	55,161	65,895
Deferred rent—noncurrent		4,092
Lease liabilities—noncurrent	9,121
Total liabilities	98,593	96,919
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.0001 par value— 10,000,000 shares authorized as of June 30, 2020 and December 31, 2019; no shares issued and outstanding as of June 30, 2020 and December 31, 2019
Additional paid-in capital	323,155	316,333
Accumulated deficit	(236,604)	(177,067)
Treasury stock	(952)	(952)
Total stockholders’ equity	85,599	138,314
Total liabilities and stockholders’ equity	$ 184,192	$ 235,233

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.000005	$ 0.000005
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	52,978,901	51,965,708
Common stock, shares outstanding	52,168,429	51,155,236

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenue	$ 1,078	$ 5,389	$ 8,076	$ 10,851
Operating expenses
Research and development	25,183	22,760	50,062	42,721
General and administrative	8,703	6,500	18,318	11,495
Total operating expenses	33,886	29,260	68,380	54,216
Loss from operations	(32,808)	(23,871)	(60,304)	(43,365)
Other income (expense), net:
Change in fair value of convertible notes payable		2,950		(9,758)
Interest expense				(182)
Interest income	107	1,485	767	2,086
Total other income (expense), net	107	4,435	767	(7,854)
Net loss and net loss attributable to common stockholders	$ (32,701)	$ (19,436)	$ (59,537)	$ (51,219)
Net loss per share attributable to common stockholders- basic and diluted	$ (0.63)	$ (0.39)	$ (1.15)	$ (1.55)
Weighted average shares of common stock outstanding- basic and diluted	51,909,240	50,035,370	51,611,005	33,095,314

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Series A Convertible Preferred Stock	Series B Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Treasury Stock
Beginning balance at Dec. 31, 2018	$ 39,960	$ 3	$ 2		$ 126,094	$ (85,187)	$ (952)
Beginning balance, Shares at Dec. 31, 2018		25,650,000	21,956,095	16,717,117
Adjustment to beginning accumulated deficit from adoption of ASU 2014-09 at Dec. 31, 2018	997					997
Stock option exercises	107				107
Stock option exercises, Shares				145,975
Share-based compensation expense	1,549				1,549
Net loss	(31,783)					(31,783)
Ending balance at Mar. 31, 2019	10,830	$ 3	$ 2		127,750	(115,973)	(952)
Ending balance, Shares at Mar. 31, 2019		25,650,000	21,956,095	16,863,092
Beginning balance at Dec. 31, 2018	39,960	$ 3	$ 2		126,094	(85,187)	(952)
Beginning balance, Shares at Dec. 31, 2018		25,650,000	21,956,095	16,717,117
Adjustment to beginning accumulated deficit from adoption of ASU 2014-09 at Dec. 31, 2018	997					997
Net loss	(51,219)
Ending balance at Jun. 30, 2019	173,978				310,339	(135,409)	(952)
Ending balance, Shares at Jun. 30, 2019				51,401,015
Beginning balance at Mar. 31, 2019	10,830	$ 3	$ 2		127,750	(115,973)	(952)
Beginning balance, Shares at Mar. 31, 2019		25,650,000	21,956,095	16,863,092
Conversion of convertible preferred stock into common stock upon initial public offering		$ (3)	$ (2)		5
Issuance of common stock upon conversion of convertible notes	49,490				49,490
Issuance of common stock in initial public offering, net of discounts and issuance costs	130,543				130,543
Stock option exercises	272				272
Stock option exercises, Shares				230,272
Share-based compensation expense	2,279				2,279
Net loss	(19,436)					(19,436)
Ending balance at Jun. 30, 2019	173,978				310,339	(135,409)	(952)
Ending balance, Shares at Jun. 30, 2019				51,401,015
Conversion of convertible preferred stock into common stock upon initial public offering, shares		(25,650,000)	(21,956,095)	22,301,190
Issuance of common stock upon conversion of convertible notes, shares				2,921,461
Issuance of common stock in initial public offering, net of discounts and issuance costs, shares				9,085,000
Beginning balance at Dec. 31, 2019	138,314				316,333	(177,067)	(952)
Beginning balance, Shares at Dec. 31, 2019				51,965,708
Stock option exercises	212				212
Stock option exercises, Shares				244,999
Issuance of common stock under employee stock purchase plan	239				239
Issuance of common stock under employee stock purchase plan, Shares				42,620
Share-based compensation expense	3,105				3,105
Net loss	(26,836)					(26,836)
Ending balance at Mar. 31, 2020	115,034				319,889	(203,903)	(952)
Ending balance, Shares at Mar. 31, 2020				52,253,327
Issuance of common stock under employee stock purchase plan, Shares				42,620
Beginning balance at Dec. 31, 2019	$ 138,314				316,333	(177,067)	(952)
Beginning balance, Shares at Dec. 31, 2019				51,965,708
Stock option exercises, Shares	970,573
Net loss	$ (59,537)
Ending balance at Jun. 30, 2020	85,599				323,155	(236,604)	(952)
Ending balance, Shares at Jun. 30, 2020				52,978,901
Beginning balance at Mar. 31, 2020	115,034				319,889	(203,903)	(952)
Beginning balance, Shares at Mar. 31, 2020				52,253,327
Stock option exercises	148				148
Stock option exercises, Shares				725,574
Share-based compensation expense	3,118				3,118
Net loss	(32,701)					(32,701)
Ending balance at Jun. 30, 2020	$ 85,599				$ 323,155	$ (236,604)	$ (952)
Ending balance, Shares at Jun. 30, 2020				52,978,901

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (59,537)	$ (51,219)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,358	2,107
Share-based compensation	6,223	3,828
Loss on disposal of assets		22
Non-cash interest expense		182
Change in fair value of convertible notes payable		9,758
Amortization of right-of-use assets	485
Changes in operating assets and liabilities:
Prepaid expenses	(687)	648
Accounts receivable	882	273
Other assets and other current assets	1,913	(852)
Accounts payable	(121)	207
Accrued other expenses and other current liabilities	(226)	2,436
Deferred revenue	(4,160)	(3,872)
Lease liabilities and right-of-use assets	(841)
Net cash used in operating activities	(51,711)	(36,482)
Cash flows from investing activities:
Purchases of property, equipment and software	(2,888)	(13,219)
Net cash used in investing activities	(2,888)	(13,219)
Cash flows from financing activities:
Proceeds from stock option exercises	360	379
Proceeds from employee stock purchase plan	239
Deferred offering costs		(2,507)
Issuance of convertible notes		39,550
Proceeds from IPO, net of underwriting discounts and commissions		135,185
Net cash provided by financing activities	599	172,607
Net increase (decrease) in cash and cash equivalents	(54,000)	122,906
Cash and cash equivalents—beginning of period	180,886	103,193
Cash and cash equivalents —end of period	126,886	226,099
Supplemental disclosures of noncash financing and investing activities:
Common stock issued on conversion of convertible notes		49,490
Property, equipment and software additions included in accounts payable, accrued expenses and other current liabilities	$ 471	$ 2,052

Description of Business and Sum

Description of Business and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1: DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of Business Precision BioSciences, Inc. (the “Company”) was incorporated on January 26, 2006 under the laws of the State of Delaware and is based in Durham, North Carolina. The Company is dedicated to improving life through the application of its pioneering, proprietary ARCUS genome editing platform to treat human diseases and create healthy and sustainable food and agricultural solutions. The Company is actively developing product candidates through two reportable segments: Therapeutics and Food. The Therapeutics segment is focused on allogeneic CAR T cell immunotherapy and in vivo The Company’s wholly (100%) owned subsidiary, Precision PlantSciences, Inc., was incorporated on January 4, 2012. Precision PlantSciences, Inc. amended its certificate of incorporation on January 16, 2018 to change its name to Elo Life Systems, Inc. Elo Life Systems Australia Pty Ltd was incorporated on May 29, 2018 as a 100% owned subsidiary of Elo Life Systems, Inc. Additionally, the Company’s 100% owned subsidiary Precision BioSciences UK Limited was incorporated on June 17, 2019. The accompanying condensed consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances and transactions have been eliminated in consolidation. Since its inception, the Company has devoted substantially all of its efforts to research and development activities, recruiting skilled personnel, developing manufacturing processes, establishing its intellectual property portfolio and providing general and administrative support for these operations. The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development and clinical manufacturing of its product candidates. The Company’s success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, obtain regulatory approval of its products, successfully commercialize its products, generate revenue, meet its obligations, and, ultimately, attain profitable operations. On April 1, 2019, the Company completed its initial public offering (“IPO”) in which the Company issued and sold 9,085,000 shares In connection with the IPO, on March 15, 2019 the Company effected a reverse split of shares of the Company’s common stock on a 1-for-2.134686 basis (the “Reverse Stock Split”) of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for the Company’s Series A and Series B preferred stock. Accordingly, all common shares, stock option shares, and per share amounts for all periods presented in the accompanying financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect this Reverse Stock Split and adjustment of the preferred stock conversion ratios. Authorized common shares were not affected by the Reverse Stock Split. Upon the closing of the IPO, all of the outstanding shares of convertible preferred stock automatically converted into 22,301,190 shares of common stock at the applicable ratio then in effect and the outstanding convertible notes payable including accrued interest were settled into 2,921,461 shares of common stock (see Note 5). Subsequent to the closing of the IPO, there were no shares of Series A or Series B convertible preferred stock or convertible notes payable outstanding. Management believes that existing cash, cash equivalents and available credit will allow the Company to continue its operations into 2022. In the absence of a significant source of recurring revenue, the continued viability of the Company beyond that point is dependent on its ability to continue to raise additional capital to finance its operations. There can be no assurance that the Company will be able to obtain sufficient capital to cover its costs on acceptable terms, if at all. Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements and notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and note disclosures normally included in the annual financial statements, prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”), have been condensed or omitted pursuant to those rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 10, 2020. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair presentation of the Company’s consolidated financial position as of June 30, 2020 and consolidated results of operations for the three and six months ended June 30, 2020 and 2019 and the consolidated cash flows for the six months ended June 30, 2020 and 2019, have been made. The Company’s consolidated results of operations for the three and six months ended June 30, 2020 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2020. Summary of Significant Accounting Policies Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases Financial Instruments — Credit losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842), At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. Lease liabilities and corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as prepaid and deferred rent. In calculating the present value of the lease payments, the Company has elected to apply the discount rate based on the remaining lease term as of the transition date, January 1, 2020. However, as the rate implicit in the lease is not readily determinable, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. The Company has elected to account for the lease and non-lease components of each of its operating leases as a single lease component. The operating right-of-use asset recorded on the balance sheet is amortized on a straight-line basis as lease expense. Revenue Recognition for Contracts with Customers The Company’s revenues are generated primarily through collaborative research, license, development and commercialization agreements. Effective January 1, 2019, the Company adopted ASU No. 2014-09, Revenue: Revenue from Contracts with Customers Revenue Recognition At contract inception, once the contract is determined to be within the scope of ASC 606, the Company evaluates the performance obligations promised in the contract that are based on goods and services that will be transferred to the customer and determines whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. Goods or services that meet these criteria are considered distinct performance obligations. If both these criteria are not met, the goods and services are combined into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, these options are considered performance obligations. The exercise of a material right is accounted for as a contract modification for accounting purposes. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method. For the six months ended June 30, 2020, the Company recorded cumulative catch up adjustments that reduced revenue recognition by $6.6 million, in addition to a contract liability adjustment, for changes in total estimated effort to be incurred in the future to satisfy the performance obligation. Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue within current liabilities in the accompanying condensed consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue – noncurrent. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets in the Other current assets line item in the condensed consolidated balance sheets. Milestone Payments – If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. Royalties – For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. Significant Financing Component – In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed each of its revenue arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements. Collaborative Arrangements – The Company has entered into collaboration agreements, which are within the scope of ASC 606, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (1) licenses, or options to obtain licenses, to use the Company’s technology, (2) research and development activities to be performed on behalf of the collaboration partner, and (3) in certain cases, services in connection with the manufacturing of preclinical and clinical material. Payments the Company receives under these arrangements typically include one or more of the following: non-refundable, upfront license fees; option exercise fees; funding of research and/or development efforts; clinical and development, regulatory, and sales milestone payments; and royalties on future product sales. The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements For a complete discussion of accounting for collaboration revenues, see Note 8, “Collaboration and license agreements.” Accounting Standards Updates In February 2016, the FASB issued ASU 2016-02, Leases Financial Instruments — Credit losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842), In May 2014, the Financial Accounting Standards Board, or FASB, issued ASC 606, which superseded the revenue requirements in ASC 605. In 2015 and 2016, the FASB issued additional ASUs related to ASC 606 that delayed the effective date of the guidance and clarified various aspects of the new revenue guidance, including principal versus agent considerations, identifying performance obligations, and licensing, and they include other improvements and practical expedients. Effective January 1, 2019, the Company adopted ASC 606 using the modified retrospective transition method. As a result of adopting ASC 606, the Company recorded a $1.0 million transition adjustment in the first quarter of 2019 to reduce the opening balance of accumulated deficit as of January 1, 2019 primarily as a result of the treatment of the up-front consideration received from the Company’s collaboration agreements under prior revenue recognition guidance. During the six months ended June 30, 2020, the Company recognized $4.2 million in revenue that was included in the deferred revenue balance as of December 31, 2019. Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measuremen In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and ASC 606

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2020
Stockholders Equity Note [Abstract]
STOCKHOLDERS' EQUITY	NOTE 2 : STOCKHOLDERS’ EQUITY Capital Structure Upon the closing of the IPO, all of the Company’s outstanding shares of the Series A and Series B convertible preferred stock automatically converted into 22,301,190 shares of common stock and the Company’s outstanding convertible notes payable including accrued interest converted into 2,921,461 shares of common stock at the applicable conversion ratio. Subsequent to the closing of the IPO, there were no shares of preferred stock outstanding. On April 1, 2019, the Company filed an amendment to its amended and restated certificate of incorporation pursuant to which, among other things, the Company increased its authorized shares to 210,000,000 shares of capital stock, of which 200,000,000 shares were designated as $0.000005 par value common stock and 10,000,000 shares were designated as $0.0001 par value preferred stock.

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
SHARE-BASED COMPENSATION	NOTE 3 : SHARE-BASED COMPENSATION Under the terms of its equity incentive award plans, the Company’s board of directors may grant equity or equity-based awards to employees, directors and service providers. The Company granted stock options under the 2006 Stock Incentive Plan (“2006 Plan”) until April 2015 when the 2015 Stock Incentive Plan (“2015 Plan”) was adopted. The 2006 Plan expired in 2016 and there are no remaining shares available to be granted under the 2006 Plan. There were 758,080 stock options outstanding under the 2006 Plan as of June 30, 2020. Upon adoption of the 2015 Plan, there were 5,270,095 shares of common stock reserved for issuance. In May 2018, the Company amended the 2015 Plan to increase the number of shares reserved for issuance to 8,211,980. The 2015 Plan had 4,921,312 stock options outstanding as of June 30, 2020. The Company’s board of directors determines the terms of stock options granted under the 2015 Plan, including option exercise prices and vesting. On March 12, 2019, the Company’s board of directors adopted, and the Company’s stockholders approved the Precision BioSciences, Inc. 2019 Incentive Award Plan (“2019 Plan”) and the 2019 Employee Stock Purchase Plan (“2019 ESPP”), both of which became effective on March 27, 2019. On March 27, 2019, the Company ceased granting new awards under the 2015 Plan. The 2019 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units and other share-based awards initially equal to 4,750,000 shares of common stock. The 2019 Plan provides for an annual increase to the number of shares of common stock available for issuance on the first day of each calendar year beginning January 1, 2020 and ending on and including January 1, 2029 by an amount equal to the lesser of (i) 4% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the board of directors. The number of shares available for issuance under the 2019 Plan was increased by 2,046,209 on January 1, 2020 pursuant to this provision. Any shares that are subject to awards outstanding under the Company’s 2006 Plan and 2015 Plan as of the effective date of the 2019 Plan that expire, lapse, or are terminated, exchanged for cash, surrendered, repurchased, or canceled without having been fully exercised or forfeited, to the extent so unused, will become available for award grants under the 2019 Plan. The 2019 Plan had 4,296,545 stock options outstanding as of June 30, 2020. Up to 525,000 shares of the Company’s common stock were initially reserved for issuance under the 2019 ESPP. The 2019 ESPP provides for an annual increase to the number of shares available for issuance on the first day of each calendar year beginning January 1, 2020 and ending on and including January 1, 2029 by an amount equal to the lesser of (i) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by our board of directors. The number of shares available for issuance under the 2019 ESPP was increased by 511,552 shares on January 1, 2020 pursuant to this provision. No more than 5,250,000 shares of our common stock may be issued under our 2019 ESPP. The purchase price of the shares, in the absence of a contrary designation, will be 85% of the lower of the fair market value of our common stock on the first trading day of the offering period or on the purchase date. The first ESPP offering period commenced on October 21, 2019 and ended on February 29, 2020; 42,620 shares were issued with respect to this offering period. The next ESPP offering period commenced on March 1, 2020 and will end on August 31, 2020. The Company recorded employee and nonemployee share-based compensation expense as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Employee $ 2,850 $ 2,138 $ 5,779 $ 3,577 Nonemployee 268 141 444 251 $ 3,118 $ 2,279 $ 6,223 $ 3,828 Share-based compensation expense related to stock options is included in the following line items in the condensed Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Research and development $ 1,953 $ 1,510 $ 3,808 $ 2,516 General and administrative 1,165 769 2,415 1,312 $ 3,118 $ 2,279 $ 6,223 $ 3,828 Determining the appropriate fair value model to measure the fair value of the stock option grants on the date of grant and the related assumptions requires judgment. The fair value of each stock option grant is estimated using a Black-Scholes option-pricing model on the date of grant as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2020 Estimated dividend yield 0.00 % 0.00 % Weighted-average expected stock price volatility 74.09 % 73.82 % Weighted-average risk-free interest rate 0.54 % 0.69 % Expected life of options (in years) 6.56 6.57 Weighted-average fair value per option $ 4.54 $ 5.12 The expected volatility rates are estimated based on the actual volatility of comparable public companies over the expected term. The expected term represents the average time that stock options that vest are expected to be outstanding. The Company does not have sufficient history of exercising stock options to estimate the expected term of employee stock options and thus utilizes a weighted value considering actual history and estimated expected term based on the midpoint of final vest date and expiration date. The risk-free rate is based on the United States Treasury yield curve during the expected life of the option. The following table summarizes activity in the Company’s stock option plans for the six months ended June 30, 2020: Outstanding Option Shares Weighted-Average Exercise Price Balance as of January 1, 2020 8,919,116 $ 7.02 Granted 2,576,567 7.71 Exercised (970,573 ) 0.37 Forfeited/canceled (549,173 ) 7.76 Balance as of June 30, 2020 9,975,937 $ 7.81 The intrinsic value of stock options exercised was $6.7 million and $4.6 million during the six months ended June 30, 2020 and 2019, respectively. There was approximately $33.6 million of total unrecognized compensation cost related to unvested stock options as of June 30, 2020, which is expected

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 4 : COMMITMENTS AND CONTINGENCIES Litigation The Company is not subject to any material legal proceedings. COVID-19 Pandemic In March 2020, the World Health Organization designated the outbreak of the novel strain of coronavirus known as COVID-19 as a global pandemic. The Company has taken steps in line with guidance from the U.S. Centers for Disease Control and Prevention (“CDC”) and the State of North Carolina to protect the health and safety of its employees and the community. In particular, the Company has implemented a work-from-home policy and has restricted on-site activities, including certain manufacturing functions and limited laboratory and support activities. The Company is working closely with its clinical sites, physician partners and the patient community to monitor and manage the impact of the COVID-19 pandemic. The Company remains committed to its clinical programs and development plans, however, disruptions, competing resource demands and safety concerns caused by the COVID-19 pandemic have caused delays in the Company’s clinical trial site activation and impacted its ability to enroll patients. The Company may also experience other difficulties, disruptions or delays in conducting preclinical studies or initiating, enrolling, conducting or completing its planned and ongoing clinical trials, and the Company may incur other unforeseen costs as a result. While the extent to which COVID-19 may continue to impact the Company’s future results will depend on future developments, the pandemic and associated economic impacts could result in a material impact to the Company’s future financial condition, results of operations and cash flows. The Company is continuing to assess the impact of the COVID-19 pandemic to best mitigate risk and continue the operations of its business. Leases The Company has operating leases for real estate in North Carolina and does not have any finance leases. During the six months ended June 30, 2020, the Company entered into three related amendments to an existing real estate lease for additional space. The Company is involved in the construction and design of the space and anticipates that it will incur construction costs, subject to an allowance for tenant improvements of up to $0.9 million. The lease expires on August 31, 2027. The base rent is $0.5 million per year, subject to an annual upward adjustment of 3.0%, and the Company is subject to a two month free-rent period. Variable lease payments include the Company’s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. The lease commencement date, for accounting purposes, was not reached as of June 30, 2020 and therefore the lease is not included in the Company’s operating lease right-of-use asset or operating lease liabilities as of June 30, 2020. As part of the amendments, upon construction completion, the term of the existing space will be extended by one year, through August 31, 2027. Many of the Company’s leases contain options to renew and extend lease terms and options to terminate leases early. Reflected in the right-of-use asset and lease liability on the Company’s balance sheet are the periods provided by renewal and extension options that the Company is reasonably certain to exercise, as well as the periods provided by termination options that the Company is reasonably certain to not exercise. The Company has existing leases that include variable lease payments that are not included in the right-of-use asset and lease liability and are reflected as an expense in the period incurred. Such payments primarily include common area maintenance charges and fluctuations in rent payments that are driven by factors such as future changes in an index (e.g. the Consumer Price Index). The Company has existing net leases in which the non-lease components (e.g., common area maintenance, consumables, etc.) are paid separately from rent based on actual costs incurred and therefore are not included in the right-of-use asset and lease liability but rather reflected as an expense in the period incurred. As of June 30, 2020, right-of-use assets of $6.5 million, current lease liabilities of $1.8 million, and non-current lease liabilities of $9.1 million are reflected on the balance sheet. The elements of lease expense were as follows: Six Months Ended June 30, (in thousands) 2020 Lease Cost Operating lease cost $ 942 Short-term lease cost 237 Variable lease cost 466 Total Lease Cost $ 1,645 Other Information Operating cash flows used for operating leases 1,276 Operating lease liabilities arising from obtaining right-of-use assets 157 Operating Leases Weighted average remaining lease term (in years) 4.9 Operating Leases Weighted average discount rate 8.3 % Future lease payments under non-cancelable leases with terms of greater than one year as of June 30, 2020, were as follows: (in thousands) June 30, 2020 2020 (excluding the 6 months ended June 30, 2020) $ 1,292 2021 2,674 2022 2,758 2023 2,836 2024 2,128 2025 and beyond 1,639 Total lease payments 13,327 Less: imputed interest 2,406 Total operating lease liabilities $ 10,921 Minimum lease payments under operating leases as of December 31, 2019 under superseded ASC 840 Leases accounting guidance were as follows: (in thousands) December 31, 2019 2020 $ 2,706 2021 3,099 2022 3,196 2023 3,288 2024 2,611 2025 and beyond 3,066 Total minimum lease payments $ 17,966 Supply Agreements The Company enters into contracts in the normal course of business with contract manufacturing organizations (“CMOs”) for the manufacture of clinical trial materials and contract research organizations (“CROs”) for clinical trial services. These agreements provide for termination at the request of either party with less than one-year notice and are, therefore, cancelable contracts and, if canceled, are not anticipated to have a material effect on the condensed

Debt

Debt	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
DEBT	NOTE 5 : DEBT In March 2019, the Company entered into a note purchase agreement pursuant to which it sold and issued an aggregate of $39.6 million of convertible notes payable (the “2019 Notes”). The 2019 Notes accrued interest at a rate of 6% per annum. The 2019 Notes were settled in 2,921,461 shares of common stock in connection with the closing of the Company’s IPO (see Note 1) at a settlement price of $13.60 per share (equal to 85% of the IPO price per share). On issuance, the Company elected to account for the 2019 Notes at fair value with any changes in fair value being recognized through the condensed consolidated statements of operations until the 2019 Notes are settled. The fair value of the 2019 Notes was determined to be $39.6 million on issuance and $49.4 million as of April 1, 2019, the settlement date. Revolving Line On June 23, 2020, the Company and Pacific Western Bank (“Bank”) entered into the Third Amendment to Loan and Security Agreement to the revolving line of credit agreement dated as of May 15, 2019 (as amended, the “Pacific Western Loan”). The aggregate principal amount under the Pacific Western Loan is $30.0 million. The Pacific Western Loan matures on June 23, 2022, provided that, if the Company receives aggregate cash proceeds of at least $125.0 million from the issuance of the Company’s equity securities and/or upfront cash proceeds from strategic partnerships on terms and conditions reasonably satisfactory to the Bank, the maturity date shall then instead be June 23, 2023. All outstanding principal amounts are due on the maturity date. The Company must also maintain an aggregate balance of unrestricted cash at Bank (not including amounts in certain specified accounts) equal to or greater than $10.0 million. The interest rate under the Pacific Western Loan is a variable annual rate equal to the greater of (a) 2.75% above the Prime Rate (as defined in the Pacific Western Loan), or (b) 6.00%. There were no borrowings, and the Company was in compliance with its financial covenants, under the Pacific Western Loan as of June 30, 2020.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 6 : Income Taxes The Company estimates an annual effective tax rate of 0% for the year ending December 31, 2020 as the Company incurred losses for the six months ended June 30, 2020 and is forecasting additional losses through the remainder of fiscal year ending December 31, 2020, resulting in an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2020. Therefore, no federal or state income taxes are expected and none have been recorded at this time. Income taxes have been accounted for using the liability method. Due to the Company's history of losses since inception, there is not enough evidence at this time to support that the Company will generate future income of a sufficient amount and nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a full valuation allowance, since the Company does not currently believe that realization of its deferred tax assets is more likely than not. As of June 30, 2020, the Company had no unrecognized income tax benefits that would reduce the Company’s effective tax rate if recognized.

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 7 : FAIR VALUE MEASUREMENTS The carrying amounts of the Company’s financial instruments, including accounts receivable, accounts payable, and accrued expenses and other current liabilities, approximate their respective fair values due to their short-term nature. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis and to minimize the use of unobservable inputs when determining their fair value. The three tiers are defined as follows: Level 1—Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities Level 2—Inputs, other than quoted prices in active markets, that are observable either directly or indirectly Level 3—Unobservable inputs for which there is little or no market date, which require the Company to develop its own assumptions The Company classifies investments in money market funds within Level 1 as the prices are available from quoted prices in active markets. Investments in repurchase agreements are classified within Level 2 as these instruments are valued using observable market inputs including reported trades, broker/dealer quotes, bids and/or offers. As of June 30, 2020 and December 31, 2019, the Company held cash equivalents which are composed of money market funds and repurchase agreements that were purchased through repurchase intermediary banks and collateralized by deposits in the form of government securities and obligations. The following represents assets measured at fair value on a recurring basis by the Company (in thousands): June 30, 2020 Fair Value Level 1 Level 2 Level 3 Assets: Money market funds $ 103,356 $ 103,356 $ — $ — Repurchase agreements 20,000 — 20,000 — $ 123,356 $ 103,356 $ 20,000 $ — December 31, 2019 Fair Value Level 1 Level 2 Level 3 Assets: Money market funds $ 3,395 $ 3,395 $ — $ — Repurchase agreements 173,000 — 173,000 — $ 176,395 $ 3,395 $ 173,000 $ —

Collaboration and License Agree

Collaboration and License Agreements	6 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
COLLABORATION AND LICENSE AGREEMENTS	NOTE 8 : COLLABORATION AND LICENSE AGREEMENTS Development and Commercial License Agreement with Servier On February 24, 2016, the Company entered into a development and commercial license agreement, as subsequently amended, with predecessor entities to Servier. This agreement establishes a collaboration between the Company and Servier to develop allogeneic chimeric antigen receptor T (“CAR T”) cell therapies for up to six unique antigen targets selected by Servier. Servier selected one target at the agreement’s inception. The Company granted Servier a development license and will perform early-stage R&D on the selected targets and develop the resulting therapeutic product candidates through Phase 1 clinical trials and manufacture clinical trial material for use in Phase 2 clinical trials. Also, the Company and Servier have formed a joint steering committee (“JSC”) to provide high-level oversight and decision making regarding the activities covered under the agreement. The Company recognizes revenue from the upfront payment of $105.0 million based on an input method in the form of research effort relative to expected research effort at the completion of the performance obligation, which is based on the actual time of R&D activities performed relative to expected time to be incurred in the future to satisfy the performance obligation. Management evaluates and adjusts the total expected research effort for the performance obligation on a quarterly basis based upon actual research accomplishments, changes in research approach as determined by the JSC, Servier’s selection and direction on antigen targets, and the probability of continuing research efforts in the future. The transfer of control occurs over this time period and, in management’s judgment, is the best measure of progress towards satisfying the performance obligation. The remaining performance obligation associated with the $105.0 million upfront payment is expected to be satisfied over an approximate 5 year period as of June 30, 2020. During the six months ended June 30, 2020 and 2019, the Company recognized revenue under the agreement with Servier of approximately $2.6 million and $3.0 million, respectively. Deferred revenue related to the agreement with Servier amounted to $78.2 million and $80.9 million as of June 30, 2020 and December 31, 2019, respectively, of which $23.1 million and $15.0 million, respectively is included in current liabilities. No development or sales-based milestone payments were received during the six months ended June 30, 2020 and 2019. Collaboration and License Agreement with Gilead On July 6, 2020 (the “Termination Notice Date”), Gilead Sciences (“Gilead”) notified the Company of its termination of the Collaboration and License Agreement between Gilead and the Company, dated September 10, 2018, as subsequently amended by Amendment No. 1 to the Collaboration and License Agreement, dated March 10, 2020 (as amended, the “Gilead Agreement”). Pursuant to the termination notice, the Gilead Agreement will terminate effective September 4, 2020. Upon termination, the Company will regain full rights and all data it generated for the in vivo Revenue associated with the combined performance obligation was recognized on a straight-line basis as the R&D services were provided through the Termination Notice Date. During the six months ended June 30, 2020 and 2019, the Company recognized revenue under the Gilead Agreement of approximately $3.9 million and $6.7 million, respectively. The Company did not have deferred revenue related to the Gilead Agreement as of June 30, 2020. Deferred revenue amounted to $1.5 million as of December 31, 2019. No development or sales-based milestone payments were received during the six months ended June 30, 2020.

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
SEGMENT REPORTING	NOTE 9 : SEGMENT REPORTING The Company has developed a genome editing platform and performed related research for human therapeutic and agricultural applications. The Company’s Chief Operating Decision Maker (“CODM”) evaluates the Company’s financial performance based on two reportable segments: Therapeutics and Food. The Therapeutics segment is focused on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment is focused on applying ARCUS to develop food and nutrition products through collaboration agreements with consumer-facing companies. The CODM reviews segment performance and allocates resources based upon segment revenue and segment operating loss of the Therapeutics and Food reportable segments. Segment operating loss is derived by deducting operational cash expenditures, net, from GAAP revenue. Operational cash expenditures are cash disbursements made that are directly attributable to the reportable segment (including directly attributable research and development and property, equipment, and software expenditures). The Company previously allocated centralized research and development expenditures for early stage research, nuclease development and the purchase of general laboratory supplies to the Therapeutics and Food segments based on headcount and presented such allocated expenditures separately from segment operational cash expenditures. Beginning January 1, 2020, such allocated expenditures are included within segment operational cash expenditures. Prior period information was presented consistent with the current period presentation. Certain cost items are not allocated to the Company’s reportable segments. These cost items primarily consist of compensation and general operational expenses associated with the Company’s executive, business development, finance, operations, human resources and legal functions. The Company does not allocate non-cash income statement amounts to its reportable segments, such as share based compensation, depreciation and amortization, intangible asset impairment charges, non-cash interest expense and losses on the disposal of assets. When reconciling segment operating loss to consolidated loss from operations, the Company makes an adjustment to convert the cash expenditures to the accrual basis to reflect GAAP. All segment revenue is earned in the United States and there are no intersegment revenues. Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources. Presented below is the financial information with respect to the Company’s reportable segments: Three Months Ended June 30, (in thousands) 2020 2019 Change Revenue: Therapeutics $ 1,020 $ 4,819 $ (3,799 ) Food 58 570 (512 ) Total segment revenue 1,078 5,389 (4,311 ) Segment operational cash expenditures: Therapeutics 19,117 17,990 1,127 Food 1,588 2,077 (489 ) Total segment operational cash expenditures 20,705 20,067 638 Segment operating loss: Therapeutics (18,097 ) (13,171 ) (4,926 ) Food (1,530 ) (1,507 ) (23 ) Total segment operating loss (19,627 ) (14,678 ) (4,949 ) Adjustments to reconcile segment operating loss to consolidated loss from operations: Corporate general and administrative cash expenditures (10,714 ) (11,123 ) 409 Interest income received (107 ) (1,485 ) 1,378 Depreciation and amortization (2,203 ) (1,168 ) (1,035 ) Amortization of right-of-use asset (250 ) — (250 ) Share-based compensation (3,118 ) (2,279 ) (839 ) Loss on disposal of assets — (22 ) 22 Changes in prepaid expenses, accounts payable and accrued expenses 3,211 6,884 (3,673 ) Total consolidated loss from operations $ (32,808 ) $ (23,871 ) $ (8,937 ) Six Months Ended June 30, (in thousands) 2020 2019 Change Revenue: Therapeutics $ 6,493 $ 9,638 $ (3,145 ) Food 1,583 1,213 370 Total segment revenue 8,076 10,851 (2,775 ) Segment operational cash expenditures: Therapeutics $ 38,374 $ 34,653 $ 3,721 Food 4,406 4,184 222 Total segment operational cash expenditures 42,780 38,837 3,943 Segment operating loss: Therapeutics $ (31,881 ) $ (25,015 ) $ (6,866 ) Food (2,823 ) (2,971 ) 148 Total segment operating loss (34,704 ) (27,986 ) (6,718 ) Adjustments to reconcile segment operating loss to consolidated loss from operations: Corporate general and administrative cash expenditures $ (16,617 ) $ (18,145 ) $ 1,528 Interest income received (767 ) (2,086 ) 1,319 Depreciation and amortization (4,358 ) (2,107 ) (2,251 ) Amortization of right-of-use asset (485 ) — (485 ) Share-based compensation (6,223 ) (3,828 ) (2,395 ) Loss on disposal of assets — (22 ) 22 Changes in prepaid expenses, accounts payable and accrued expenses 2,850 10,809 (7,959 ) Total consolidated loss from operations $ (60,304 ) $ (43,365 ) $ (16,939 )

Description of Business and S_2

Description of Business and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Leases	Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases Financial Instruments — Credit losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842), At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. Lease liabilities and corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as prepaid and deferred rent. In calculating the present value of the lease payments, the Company has elected to apply the discount rate based on the remaining lease term as of the transition date, January 1, 2020. However, as the rate implicit in the lease is not readily determinable, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. The Company has elected to account for the lease and non-lease components of each of its operating leases as a single lease component. The operating right-of-use asset recorded on the balance sheet is amortized on a straight-line basis as lease expense.
Revenue Recognition for Contracts with Customers	Revenue Recognition for Contracts with Customers The Company’s revenues are generated primarily through collaborative research, license, development and commercialization agreements. Effective January 1, 2019, the Company adopted ASU No. 2014-09, Revenue: Revenue from Contracts with Customers Revenue Recognition At contract inception, once the contract is determined to be within the scope of ASC 606, the Company evaluates the performance obligations promised in the contract that are based on goods and services that will be transferred to the customer and determines whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. Goods or services that meet these criteria are considered distinct performance obligations. If both these criteria are not met, the goods and services are combined into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, these options are considered performance obligations. The exercise of a material right is accounted for as a contract modification for accounting purposes. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method. For the six months ended June 30, 2020, the Company recorded cumulative catch up adjustments that reduced revenue recognition by $6.6 million, in addition to a contract liability adjustment, for changes in total estimated effort to be incurred in the future to satisfy the performance obligation. Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue within current liabilities in the accompanying condensed consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue – noncurrent. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets in the Other current assets line item in the condensed consolidated balance sheets. Milestone Payments – If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. Royalties – For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. Significant Financing Component – In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed each of its revenue arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements. Collaborative Arrangements – The Company has entered into collaboration agreements, which are within the scope of ASC 606, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (1) licenses, or options to obtain licenses, to use the Company’s technology, (2) research and development activities to be performed on behalf of the collaboration partner, and (3) in certain cases, services in connection with the manufacturing of preclinical and clinical material. Payments the Company receives under these arrangements typically include one or more of the following: non-refundable, upfront license fees; option exercise fees; funding of research and/or development efforts; clinical and development, regulatory, and sales milestone payments; and royalties on future product sales. The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements For a complete discussion of accounting for collaboration revenues, see Note 8, “Collaboration and license agreements.”
Accounting Standards Updates	Accounting Standards Updates In February 2016, the FASB issued ASU 2016-02, Leases Financial Instruments — Credit losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842), In May 2014, the Financial Accounting Standards Board, or FASB, issued ASC 606, which superseded the revenue requirements in ASC 605. In 2015 and 2016, the FASB issued additional ASUs related to ASC 606 that delayed the effective date of the guidance and clarified various aspects of the new revenue guidance, including principal versus agent considerations, identifying performance obligations, and licensing, and they include other improvements and practical expedients. Effective January 1, 2019, the Company adopted ASC 606 using the modified retrospective transition method. As a result of adopting ASC 606, the Company recorded a $1.0 million transition adjustment in the first quarter of 2019 to reduce the opening balance of accumulated deficit as of January 1, 2019 primarily as a result of the treatment of the up-front consideration received from the Company’s collaboration agreements under prior revenue recognition guidance. During the six months ended June 30, 2020, the Company recognized $4.2 million in revenue that was included in the deferred revenue balance as of December 31, 2019. Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measuremen In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and ASC 606

Share-Based Compensation (Table

Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Stock-Based Compensation Expense	The Company recorded employee and nonemployee share-based compensation expense as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Employee $ 2,850 $ 2,138 $ 5,779 $ 3,577 Nonemployee 268 141 444 251 $ 3,118 $ 2,279 $ 6,223 $ 3,828
Schedule of Stock-Based Compensation Expense	Share-based compensation expense related to stock options is included in the following line items in the condensed Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Research and development $ 1,953 $ 1,510 $ 3,808 $ 2,516 General and administrative 1,165 769 2,415 1,312 $ 3,118 $ 2,279 $ 6,223 $ 3,828
Schedule of Stock Options Valuation Assumptions Using a Black-Scholes Option Pricing Model	The fair value of each stock option grant is estimated using a Black-Scholes option-pricing model on the date of grant as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2020 Estimated dividend yield 0.00 % 0.00 % Weighted-average expected stock price volatility 74.09 % 73.82 % Weighted-average risk-free interest rate 0.54 % 0.69 % Expected life of options (in years) 6.56 6.57 Weighted-average fair value per option $ 4.54 $ 5.12
Summary of Activity of Option Plans	The following table summarizes activity in the Company’s stock option plans for the six months ended June 30, 2020: Outstanding Option Shares Weighted-Average Exercise Price Balance as of January 1, 2020 8,919,116 $ 7.02 Granted 2,576,567 7.71 Exercised (970,573 ) 0.37 Forfeited/canceled (549,173 ) 7.76 Balance as of June 30, 2020 9,975,937 $ 7.81

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Components of Lease Expense	The elements of lease expense were as follows: Six Months Ended June 30, (in thousands) 2020 Lease Cost Operating lease cost $ 942 Short-term lease cost 237 Variable lease cost 466 Total Lease Cost $ 1,645 Other Information Operating cash flows used for operating leases 1,276 Operating lease liabilities arising from obtaining right-of-use assets 157 Operating Leases Weighted average remaining lease term (in years) 4.9 Operating Leases Weighted average discount rate 8.3 %
Schedule of Future Lease Payments under Non- Canceleable Leases	Future lease payments under non-cancelable leases with terms of greater than one year as of June 30, 2020, were as follows: (in thousands) June 30, 2020 2020 (excluding the 6 months ended June 30, 2020) $ 1,292 2021 2,674 2022 2,758 2023 2,836 2024 2,128 2025 and beyond 1,639 Total lease payments 13,327 Less: imputed interest 2,406 Total operating lease liabilities $ 10,921
Schedule of Future Minimum Lease Payments	Minimum lease payments under operating leases as of December 31, 2019 under superseded ASC 840 Leases accounting guidance were as follows: (in thousands) December 31, 2019 2020 $ 2,706 2021 3,099 2022 3,196 2023 3,288 2024 2,611 2025 and beyond 3,066 Total minimum lease payments $ 17,966

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract]
Schedule of Assets Measured at Fair Value on Recurring Basis	The following represents assets measured at fair value on a recurring basis by the Company (in thousands): June 30, 2020 Fair Value Level 1 Level 2 Level 3 Assets: Money market funds $ 103,356 $ 103,356 $ — $ — Repurchase agreements 20,000 — 20,000 — $ 123,356 $ 103,356 $ 20,000 $ — December 31, 2019 Fair Value Level 1 Level 2 Level 3 Assets: Money market funds $ 3,395 $ 3,395 $ — $ — Repurchase agreements 173,000 — 173,000 — $ 176,395 $ 3,395 $ 173,000 $ —

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Financial Information with Respect to Company's Reportable Segments	Presented below is the financial information with respect to the Company’s reportable segments: Three Months Ended June 30, (in thousands) 2020 2019 Change Revenue: Therapeutics $ 1,020 $ 4,819 $ (3,799 ) Food 58 570 (512 ) Total segment revenue 1,078 5,389 (4,311 ) Segment operational cash expenditures: Therapeutics 19,117 17,990 1,127 Food 1,588 2,077 (489 ) Total segment operational cash expenditures 20,705 20,067 638 Segment operating loss: Therapeutics (18,097 ) (13,171 ) (4,926 ) Food (1,530 ) (1,507 ) (23 ) Total segment operating loss (19,627 ) (14,678 ) (4,949 ) Adjustments to reconcile segment operating loss to consolidated loss from operations: Corporate general and administrative cash expenditures (10,714 ) (11,123 ) 409 Interest income received (107 ) (1,485 ) 1,378 Depreciation and amortization (2,203 ) (1,168 ) (1,035 ) Amortization of right-of-use asset (250 ) — (250 ) Share-based compensation (3,118 ) (2,279 ) (839 ) Loss on disposal of assets — (22 ) 22 Changes in prepaid expenses, accounts payable and accrued expenses 3,211 6,884 (3,673 ) Total consolidated loss from operations $ (32,808 ) $ (23,871 ) $ (8,937 ) Six Months Ended June 30, (in thousands) 2020 2019 Change Revenue: Therapeutics $ 6,493 $ 9,638 $ (3,145 ) Food 1,583 1,213 370 Total segment revenue 8,076 10,851 (2,775 ) Segment operational cash expenditures: Therapeutics $ 38,374 $ 34,653 $ 3,721 Food 4,406 4,184 222 Total segment operational cash expenditures 42,780 38,837 3,943 Segment operating loss: Therapeutics $ (31,881 ) $ (25,015 ) $ (6,866 ) Food (2,823 ) (2,971 ) 148 Total segment operating loss (34,704 ) (27,986 ) (6,718 ) Adjustments to reconcile segment operating loss to consolidated loss from operations: Corporate general and administrative cash expenditures $ (16,617 ) $ (18,145 ) $ 1,528 Interest income received (767 ) (2,086 ) 1,319 Depreciation and amortization (4,358 ) (2,107 ) (2,251 ) Amortization of right-of-use asset (485 ) — (485 ) Share-based compensation (6,223 ) (3,828 ) (2,395 ) Loss on disposal of assets — (22 ) 22 Changes in prepaid expenses, accounts payable and accrued expenses 2,850 10,809 (7,959 ) Total consolidated loss from operations $ (60,304 ) $ (43,365 ) $ (16,939 )

Description of Business and S_3

Description of Business and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 01, 2019	Mar. 15, 2019	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jan. 01, 2020	Dec. 31, 2019	Jan. 01, 2019
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Date of incorporation				Jan. 26, 2006
issuance costs					$ 2,507
Stockholders' equity, reverse stock split		1-for-2.134686
Preferred stock, shares outstanding				0			0
Revenue recognition for changes in total estimated time to be incurred in the future to satisfy the performance obligation				$ 6,600
Lease liabilities				10,921		$ 11,600
Right-of-use assets				6,495		6,800
Reduction in deferred rent						$ 4,800
Transition adjustment to opening balance of accumulated deficit				(236,604)			$ (177,067)
Revenue recorded included in deferred revenue				$ 4,200
ASU 2014-09 | Adjustments
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Transition adjustment to opening balance of accumulated deficit								$ (1,000)
Common Stock
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Issuance of common stock upon conversion of convertible notes, shares			2,921,461
Initial Public Offering ("IPO") | Series A and Series B Convertible Preferred Stock
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Preferred stock, shares outstanding	0
Initial Public Offering ("IPO") | Common Stock
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Shares issued and sold	9,085,000
Shares issued and sold, public offering price	$ 16
Proceeds from issuance, net of underwriting discounts, commissions and issuance cost	$ 130,500
Underwriting discount and commission	10,200
issuance costs	$ 4,600
Initial Public Offering ("IPO") | Common Stock | Convertible Notes Payable (2019 Notes)
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Issuance of common stock upon conversion of convertible notes, shares	2,921,461
Initial Public Offering ("IPO") | Common Stock | Series A and Series B Convertible Preferred Stock
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Issuance of common stock upon conversion of convertible notes, shares	22,301,190
Precision PlantSciences, Inc.
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Date of incorporation				Jan. 4, 2012
Percentage owned in subsidiary				100.00%
Amended date of incorporation				Jan. 16, 2018
Amended name of incorporation				Elo Life Systems, Inc
Elo Life Systems Australia Pty Ltd | Subsidiary Issuer
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Date of incorporation				May 29, 2018
Percentage owned in subsidiary				100.00%
Precision BioSciences UK Limited
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Date of incorporation				Jun. 17, 2019
Percentage owned in subsidiary				100.00%

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - $ / shares	Apr. 01, 2019	Jun. 30, 2019	Jun. 30, 2020	Dec. 31, 2019
Stockholders' Equity [Line Items]
Preferred stock, shares outstanding			0	0
Common and prferred stocks, shares authorized	210,000,000
Common stock, shares authorized	200,000,000		200,000,000	200,000,000
Common stock, par value	$ 0.000005		$ 0.000005	$ 0.000005
Preferred stock, shares authorized	10,000,000		10,000,000	10,000,000
Preferred stock, par value	$ 0.0001		$ 0.0001	$ 0.0001
Common Stock
Stockholders' Equity [Line Items]
Common stock issued upon conversion of convertible preferred stock or convertible notes payable		2,921,461
Initial Public Offering ("IPO") | Series A and Series B Convertible Preferred Stock
Stockholders' Equity [Line Items]
Preferred stock, shares outstanding	0
Initial Public Offering ("IPO") | Common Stock | Convertible Notes Payable (2019 Notes)
Stockholders' Equity [Line Items]
Common stock issued upon conversion of convertible preferred stock or convertible notes payable	2,921,461
Initial Public Offering ("IPO") | Common Stock | Series A and Series B Convertible Preferred Stock
Stockholders' Equity [Line Items]
Common stock issued upon conversion of convertible preferred stock or convertible notes payable	22,301,190

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) - USD ($) $ in Millions	Jun. 30, 2020	Mar. 31, 2020	Mar. 12, 2019	Jun. 30, 2020	Jan. 01, 2020	Dec. 31, 2019	Jun. 30, 2019	May 31, 2018	Dec. 31, 2016	Apr. 30, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding	9,975,937			9,975,937		8,919,116
Stock options granted				2,576,567
Common stock, shares issued	52,978,901			52,978,901		51,965,708
Unrecognized compensation cost	$ 33.6			$ 33.6
Weighted-average period for recognition of compensation cost				2 years 9 months 18 days
Intrinsic value of Stock options exercised	$ 6.7			$ 6.7			$ 4.6
2006 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Remaining shares available to be granted									0
Options outstanding	758,080			758,080
2015 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding	4,921,312			4,921,312
Common stock reserved for issuance								8,211,980		5,270,095
2019 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Increase in the number of shares available			4,750,000		2,046,209
Allowed annual percentage increase in shares authorized as percentage of outstanding shares of common stock			4.00%
Stock options granted	4,296,545
2019 ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Increase in the number of shares available			525,000		511,552
Allowed annual percentage increase in shares authorized as percentage of outstanding shares of common stock			1.00%
Maximum shares allowed to be issued under ESPP			5,250,000
Purchase of common stock through payroll deductions expressed in percentage of fair market value			85.00%
Offering period commenced date		Mar. 1, 2020	Oct. 21, 2019
Offering period end date		Aug. 31, 2020	Feb. 29, 2020
Common stock, shares issued			42,620

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Employee and Nonemployee Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 3,118	$ 2,279	$ 6,223	$ 3,828
Employee
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	2,850	2,138	5,779	3,577
Nonemployee
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 268	$ 141	$ 444	$ 251

Share-Based Compensation - Sc_2

Share-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 3,118	$ 2,279	$ 6,223	$ 3,828
Stock Option
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	3,118	2,279	6,223	3,828
Research and Development | Stock Option
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	1,953	1,510	3,808	2,516
General and Administrative | Stock Option
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 1,165	$ 769	$ 2,415	$ 1,312

Share-Based Compensation - Sc_3

Share-Based Compensation - Schedule of Stock Options Valuation Assumptions Using a Black-Scholes Option Pricing Model (Details) - $ / shares	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Estimated dividend yield	0.00%	0.00%
Weighted-average expected stock price volatility	74.09%	73.82%
Weighted-average risk-free interest rate	0.54%	0.69%
Expected life of options (in years)	6 years 6 months 21 days	6 years 6 months 25 days
Weighted-average fair value per option	$ 4.54	$ 5.12

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Activity of Option Plans (Details)	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Outstanding Option Shares, Beginning Balance | shares	8,919,116
Option, Granted | shares	2,576,567
Option, Exercised | shares	(970,573)
Option, Forfeited/canceled | shares	(549,173)
Outstanding Option Shares, Ending Balance | shares	9,975,937
Weighted-Average Exercise Price Outstanding at Beginning Balance | $ / shares	$ 7.02
Weighted-Average Exercise Price, Granted | $ / shares	7.71
Weighted-Average Exercise Price, Exercised | $ / shares	0.37
Weighted-Average Exercise Price, Forfeited/canceled | $ / shares	7.76
Weighted-Average Exercise Price Outstanding at Ending Balance | $ / shares	$ 7.81

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jan. 01, 2020
Commitments And Contingencies [Line Items]
Base rent, per year	$ 500,000
Lease expiration date	Aug. 31, 2027
Percentage of annual upward adjustment of operating lease	3.00%
Term of free office rent	2 months
Lessee operating lease, option to extend	true
Operating lease renewal term	1 year
Operating lease, right-of-use assets	$ 6,495,000	$ 6,800,000
Operating lease, current lease liabilities	1,800,000
Operating lease, non-current lease liabilities	9,121,000
Maximum
Commitments And Contingencies [Line Items]
Tenant improvements allowance	$ 900,000
Agreement termination notice period	1 year

Commitments and Contingencies_2

Commitments and Contingencies - Components of Lease Expense (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Lease Cost
Operating lease cost	$ 942
Short-term lease cost	237
Variable lease cost	466
Total Lease Cost	1,645
Other Information
Operating cash flows used for operating leases	1,276
Operating lease liabilities arising from obtaining right-of-use assets	$ 157
Weighted average remaining lease term (in years)	4 years 10 months 24 days
Weighted average discount rate	8.30%

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Future Lease Payments under Non- Canceleable Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Jan. 01, 2020
Operating Leases Future Minimum Payments Due [Abstract]
2020 (excluding the 6 months ended June 30, 2020)	$ 1,292
2021	2,674
2022	2,758
2023	2,836
2024	2,128
2025 and beyond	1,639
Total lease payments	13,327
Less: imputed interest	2,406
Total operating lease liabilities	$ 10,921	$ 11,600

Commitments and Contingencies_4

Commitments and Contingencies - Schedule of Future Lease Payments (Details) $ in Thousands	Dec. 31, 2019USD ($)
Operating Leases Future Minimum Payments Due [Abstract]
2020	$ 2,706
2021	3,099
2022	3,196
2023	3,288
2024	2,611
2025 and beyond	3,066
Total minimum lease payments	$ 17,966

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 15, 2022	Jun. 23, 2020	Apr. 01, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020
Revolving Line [Member] | Pacific Western Loan Agreement
Debt Instrument [Line Items]
Aggregate principle amount		$ 30,000
Maturity of line of credit	Jun. 23, 2022
Cash proceeds from the issuance of company's equity upon loan's maturity		$ 125,000
Borrowings						$ 0
Interest rate during period						6.00%
Revolving Line [Member] | Pacific Western Loan Agreement | Prime Rate
Debt Instrument [Line Items]
Basis point added to the prime rate						2.75%
Revolving Line [Member] | Pacific Western Loan Agreement | Minimum [Member]
Debt Instrument [Line Items]
Required balance of unrestricted cash at bank	$ 10,000
Revolving Line [Member] | Revolving Line Upon Loan's Maturity | Pacific Western Loan Agreement
Debt Instrument [Line Items]
Maturity of line of credit	Jun. 23, 2023
Common Stock
Debt Instrument [Line Items]
Number of common stock issued upon settlement convertible promissory notes				2,921,461
Convertible Notes Payable (2019 Notes)
Debt Instrument [Line Items]
Aggregate principal amount			$ 39,600		$ 39,600
Notes accrued interest rate					6.00%
Settlement price equal on IPO price per Share					85.00%
Settlement Price Per Share					$ 13.60
Fair value of notes			$ 49,400
Convertible Notes Payable (2019 Notes) | Initial Public Offering ("IPO") | Common Stock
Debt Instrument [Line Items]
Number of common stock issued upon settlement convertible promissory notes			2,921,461

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Jun. 30, 2020
Income Tax Disclosure [Line Items]
Unrecognized income tax benefits		$ 0
Forecast
Income Tax Disclosure [Line Items]
Effective income tax rate	0.00%

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value Measurements Recurring - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	$ 123,356	$ 176,395
Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	103,356	3,395
Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	20,000	173,000
Repurchase Agreements
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	20,000	173,000
Repurchase Agreements | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	20,000	173,000
Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	103,356	3,395
Money Market Funds | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	$ 103,356	$ 3,395

Collaboration and License Agr_2

Collaboration and License Agreements - Additional Information (Details 1) - Servier - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2019-01-01 $ in Millions	Feb. 24, 2016USD ($)
Collaboration and License Agreements [Line items]
Revenue from upfront payment	$ 105
Estimated period performance obligation	5 years

Collaboration and License Agr_3

Collaboration and License Agreements - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Collaboration and License Agreements [Line items]
Recognized revenue under agreement			$ 4,200,000
Deferred revenue	$ 23,060,000		23,060,000		$ 16,486,000
Revenue	1,078,000	$ 5,389,000	8,076,000	$ 10,851,000
Development and Commercial License Agreement | Servier
Collaboration and License Agreements [Line items]
Recognized revenue under agreement			2,600,000	3,000,000
Deferred revenue related to agreement	78,200,000		78,200,000		80,900,000
Development or sales-based milestone payments			0	0
Development and Commercial License Agreement | Servier | Current Liabilities
Collaboration and License Agreements [Line items]
Deferred revenue	23,100,000		23,100,000		15,000,000
Collaboration and License Agreement | Gilead
Collaboration and License Agreements [Line items]
Deferred revenue	$ 0		0		$ 1,500,000
Development or sales-based milestone payments			0
Revenue			$ 3,900,000	$ 6,700,000

Segment Reporting - Additional

Segment Reporting - Additional Information (Details)	6 Months Ended
	Jun. 30, 2020Segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segment Reporting - Financial I

Segment Reporting - Financial Information with Respect to Company's Reportable Segments (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Segment Reporting Information [Line Items]
Revenue	$ 1,078	$ 5,389	$ 8,076	$ 10,851
Loss from operations	(32,808)	(23,871)	(60,304)	(43,365)
Adjustments to reconcile segment operating loss to consolidated loss from operations:
Interest income received	(107)	(1,485)	(767)	(2,086)
Depreciation and amortization			(4,358)	(2,107)
Amortization of right-of-use asset			(485)
Share-based compensation			(6,223)	(3,828)
Loss on disposal of assets				(22)
Operating Segments
Segment Reporting Information [Line Items]
Revenue	1,078	5,389	8,076	10,851
Total segment operational cash expenditures	20,705	20,067	42,780	38,837
Loss from operations	(19,627)	(14,678)	(34,704)	(27,986)
Operating Segments | Change
Segment Reporting Information [Line Items]
Revenue	(4,311)		(2,775)
Total segment operational cash expenditures	638		3,943
Loss from operations	(4,949)		(6,718)
Operating Segments | Therapeutics
Segment Reporting Information [Line Items]
Revenue	1,020	4,819	6,493	9,638
Total segment operational cash expenditures	19,117	17,990	38,374	34,653
Loss from operations	(18,097)	(13,171)	(31,881)	(25,015)
Operating Segments | Therapeutics | Change
Segment Reporting Information [Line Items]
Revenue	(3,799)		(3,145)
Total segment operational cash expenditures	1,127		3,721
Loss from operations	(4,926)		(6,866)
Operating Segments | Food
Segment Reporting Information [Line Items]
Revenue	58	570	1,583	1,213
Total segment operational cash expenditures	1,588	2,077	4,406	4,184
Loss from operations	(1,530)	(1,507)	(2,823)	(2,971)
Operating Segments | Food | Change
Segment Reporting Information [Line Items]
Revenue	(512)		370
Total segment operational cash expenditures	(489)		222
Loss from operations	(23)		148
Segment Reconciling Items
Adjustments to reconcile segment operating loss to consolidated loss from operations:
Corporate general and administrative cash expenditures	(10,714)	(11,123)	(16,617)	(18,145)
Interest income received	(107)	(1,485)	(767)	(2,086)
Depreciation and amortization	(2,203)	(1,168)	(4,358)	(2,107)
Amortization of right-of-use asset	(250)		(485)
Share-based compensation	(3,118)	(2,279)	(6,223)	(3,828)
Loss on disposal of assets		(22)		(22)
Changes in prepaid expenses, accounts payable and accrued expenses	3,211	$ 6,884	2,850	$ 10,809
Segment Reconciling Items | Change
Segment Reporting Information [Line Items]
Loss from operations	(8,937)		(16,939)
Adjustments to reconcile segment operating loss to consolidated loss from operations:
Corporate general and administrative cash expenditures	409		1,528
Interest income received	1,378		1,319
Depreciation and amortization	(1,035)		(2,251)
Amortization of right-of-use asset	(250)		(485)
Share-based compensation	(839)		(2,395)
Loss on disposal of assets	22		22
Changes in prepaid expenses, accounts payable and accrued expenses	$ (3,673)		$ (7,959)